Researchers recommend that details on prescription medications received in the year before diagnosis and treatment initiation be included in clinical trials as essential baseline information.

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

The study results “indicate that the public has certain reservations about the integration of AI in health care,” the researchers wrote.

Resources available to clinical research physicians and the expectations placed upon these individuals vary across cancer cancers, data suggest.